BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug
Study shows efficacy and safety of oral antibiotic therapy in the form of pills for Staphylococcus aureus bloodstream infections. Currently, infusions are the standard treatment / published in ‘The
INCATE (the INCubator for Antibacterial Therapies in Europe) and Kineticos AMR Accelerator Fund I (KAMRA I), have announced the beginning of a new collaboration that aims to enhance the support for
Tuberculosis is currently the infectious disease that causes the most deaths worldwide. Of particular concern is the increasing emergence of multidrug-resistant tuberculosis bacteria, particularly in
Bacteria that are resistant to broad-spectrum antibiotics from the carbapenem group are increasingly posing major problems for healthcare systems worldwide. They can cause serious infections and
Darobactin is a promising candidate for the development of new, resistance-breaking antibiotics, as it has an exceptional mechanism of action and a broad spectrum of activity. In a recent study, DZIF
INCATE, the INCubator for Antibacterial Therapies in Europe, and BIOASTER, the French Technology Research Institute, have announced this week the beginning of a new partnership that aims to improve
The Faculty of Medicine at the University of Basel has awarded an honorary doctorate to DZIF Professor Dr Stephan Urban from the Medical Faculty at the Heidelberg University. The award acknowledges
A team of researchers from Hamburg, Düsseldorf, Erlangen and Cologne has been awarded the German University Medicine Prize for curing the so-called "Düsseldorf patient", who suffered from leukaemia
"We are heading towards a crisis with our eyes wide open. Soon we will lack the antibiotics we need to perform vital operations," says Dr Timo Jäger, Managing Director of the German Center for
